内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2020 亚洲专家建议：SGLT-2抑制剂在2型糖尿病合并腹型肥胖患者中的应用

2020-02-20 国外内分泌相关专家小组（统称） Diabetes Metab J. 2020 Feb;44(1):11-32.

2型糖尿病

亚洲肥胖的患病率很高，多数2型糖尿病患者为超重或肥胖患者。这增加了这些患者的心肾风险结局。本文主要针对SGLT-2抑制剂在2性糖尿病和腹型肥胖患者中的应用提供指导建议。

中文标题：

2020 亚洲专家建议：SGLT-2抑制剂在2型糖尿病合并腹型肥胖患者中的应用

英文标题：

Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations.

发布机构：

国外内分泌相关专家小组（统称）

发布日期：

2020-02-20

简要介绍：

亚洲肥胖的患病率很高，多数2型糖尿病患者为超重或肥胖患者。这增加了这些患者的心肾风险结局。本文主要针对SGLT-2抑制剂在2性糖尿病和腹型肥胖患者中的应用提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 亚洲专家建议：SGLT-2抑制剂在2型糖尿病合并腹型肥胖患者中的应用.pdf)] GetToolGuiderByIdResponse(projectId=1, id=378b01c001900068, title=2020 亚洲专家建议：SGLT-2抑制剂在2型糖尿病合并腹型肥胖患者中的应用, enTitle=Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations., guiderFrom=Diabetes Metab J. 2020 Feb;44(1):11-32., authorId=0, author=, summary=亚洲肥胖的患病率很高，多数2型糖尿病患者为超重或肥胖患者。这增加了这些患者的心肾风险结局。本文主要针对SGLT-2抑制剂在2性糖尿病和腹型肥胖患者中的应用提供指导建议。, cover=https://img.medsci.cn/202052/1588430189903_2020535.jpg, journalId=0, articlesId=null, associationId=949, associationName=国外内分泌相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Feb 20 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>亚洲肥胖的患病率很高，多数2型糖尿病患者为超重或肥胖患者。这增加了这些患者的心肾风险结局。本文主要针对SGLT-2抑制剂在2性糖尿病和腹型肥胖患者中的应用提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2052, guiderKeyword=2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1774, appHits=163, showAppHits=51, pcHits=560, showPcHits=1652, likes=0, shares=22, comments=7, approvalStatus=1, publishedTime=Sat May 02 22:36:47 CST 2020, publishedTimeString=2020-02-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sat May 02 22:36:36 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 00:50:45 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 亚洲专家建议：SGLT-2抑制剂在2型糖尿病合并腹型肥胖患者中的应用.pdf)])
2020 亚洲专家建议：SGLT-2抑制剂在2型糖尿病合并腹型肥胖患者中的应用.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072416, encodeId=958210e2416f2, content=写的很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac85723211, createdName=ms4000000743924133, createdTime=Sun Nov 21 08:00:07 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002639, encodeId=c10a100263919, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d2f5531172, createdName=ms6000001833964428, createdTime=Mon Jul 26 03:28:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892802, encodeId=d4288928028c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:15 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809799, encodeId=fe16809e99fc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:46:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808793, encodeId=e674808e93d8, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:49 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
    2021-11-21 ms4000000743924133

    写的很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072416, encodeId=958210e2416f2, content=写的很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac85723211, createdName=ms4000000743924133, createdTime=Sun Nov 21 08:00:07 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002639, encodeId=c10a100263919, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d2f5531172, createdName=ms6000001833964428, createdTime=Mon Jul 26 03:28:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892802, encodeId=d4288928028c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:15 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809799, encodeId=fe16809e99fc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:46:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808793, encodeId=e674808e93d8, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:49 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
    2021-07-26 ms6000001833964428

    看不懂

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1072416, encodeId=958210e2416f2, content=写的很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac85723211, createdName=ms4000000743924133, createdTime=Sun Nov 21 08:00:07 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002639, encodeId=c10a100263919, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d2f5531172, createdName=ms6000001833964428, createdTime=Mon Jul 26 03:28:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892802, encodeId=d4288928028c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:15 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809799, encodeId=fe16809e99fc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:46:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808793, encodeId=e674808e93d8, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:49 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
    2020-10-18 星痕

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1072416, encodeId=958210e2416f2, content=写的很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac85723211, createdName=ms4000000743924133, createdTime=Sun Nov 21 08:00:07 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002639, encodeId=c10a100263919, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d2f5531172, createdName=ms6000001833964428, createdTime=Mon Jul 26 03:28:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892802, encodeId=d4288928028c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:15 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809799, encodeId=fe16809e99fc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:46:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808793, encodeId=e674808e93d8, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:49 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
    2020-08-17 ms5000002046462755

    好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1072416, encodeId=958210e2416f2, content=写的很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dac85723211, createdName=ms4000000743924133, createdTime=Sun Nov 21 08:00:07 CST 2021, time=2021-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002639, encodeId=c10a100263919, content=看不懂, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d2f5531172, createdName=ms6000001833964428, createdTime=Mon Jul 26 03:28:13 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892802, encodeId=d4288928028c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/1e37b07b849346038be41fe1dac7282c/3397137c98a4401787227b3a9565d458.jpg, createdBy=28372103731, createdName=星痕, createdTime=Sun Oct 18 11:30:15 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809799, encodeId=fe16809e99fc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 19:46:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808793, encodeId=e674808e93d8, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Fri Aug 14 09:59:49 CST 2020, time=2020-08-14, status=1, ipAttribution=)]
    2020-08-14 ms5000002046462755

    好

    0

相关指南

2020 AHA科学声明：2型糖尿病患者稳定性冠心病的临床管理

美国心脏协会(AHA,American Heart Association) · 2020-04-13

2019 ADA/EASD共识：2型糖尿病患者高血糖的管理（更新版）

美国糖尿病学会(ADA,American Diabetes Association) · 2019-12-19

2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病

国外内分泌相关专家小组（统称） · 2019-07-29

中国成人2型糖尿病口服降糖药联合治疗专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2019-03-03

2019 AHA/HFSA科学声明：2型糖尿病和心衰

美国心脏协会(AHA,American Heart Association) · 2019-06-06

生酮饮食干预2型糖尿病中国专家共识（2019年版）

中国内分泌相关专家小组（统称） · 2019-03-15

拓展阅读

2014 ADS立场声明：2型糖尿病血糖管理法则

澳大利亚糖尿病协会(ADS,Australian Diabetes Society) · 2014-12-11

2015 AHA/ADA科学声明：成人2型糖尿病患者心血管疾病的预防（更新版）

美国糖尿病学会(ADA,American Diabetes Association) · 2015-08-05

2015 ADA/AADE/AND联合声明：2型糖尿病的自我管理教育和支持

美国糖尿病学会(ADA,American Diabetes Association) · 2015-06-05

2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识（2015年更新版）

中国医师协会内分泌代谢科医师分会 · 2016-06-30

2013 中国2型糖尿病防治指南（2013年版）

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2014-08-16

2016 临床实践指南：成人2型糖尿病患者的预防，早期识别，诊断，管理以及随访

国外内分泌相关专家小组（统称） · 2016-06-30